Chaim Lebovits - 18 Sep 2022 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
Chief Executive Officer
Signature
/s/ Chaim Lebovits
Issuer symbol
BCLI
Transactions as of
18 Sep 2022
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 06:35:25 UTC
Previous filing
10 Dec 2021
Next filing
24 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCLI Common Stock Award $0 +31,185 +20% $0.000000 187,110 18 Sep 2022 Direct F1
holding BCLI Common Stock 2,000,847 18 Sep 2022 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.
F2 Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.